The Weight-Reducing Effect of Licogliflozin, A Novel Dual Sodium Glucose Co-Transporter 1 And 2 Inhibitor: A Systematic Review And Meta-Analysis of Randomized Controlled Trials | ||
| Egyptian Society of Diabetes and Lipidology Journal | ||
| Volume 2, Issue 2, October 2022 PDF (711.81 K) | ||
| Document Type: Abstracts | ||
| DOI: 10.21608/esdlj.2022.455810 | ||
| Abstract | ||
| Licogliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT 1, 2) inhibitor, inhibiting glucose absorption by the intestine and inhibiting glucose reabsorption by the kidney, and thus reducing calorie content. We aimed to determine the efficacy of licogliflozin on body weight blood pressure in obese/overweight participants with/without type 2 diabetes mellitus (T2DM). | ||
|
Statistics Article View: 22 PDF Download: 11 |
||
